What Comes Next For Royalty Pharma After A 78% Gain

If you had put fresh money into Royalty Pharma in early November 2025, the return now looks hard to ignore. Investors who held Royalty Pharma over the past year are up 78.0%, including dividends. That result sits next to a year where Q3 revenue was higher, yet net income was much lower and margins compressed sharply. What exactly were early buyers weighing when they chose between upbeat licensing stories and those profitability warning signs?

The easy part of this move is behind Royalty Pharma. Zero in on 39 high quality undervalued stocks for companies trading below our estimates.

The Two Royalty Pharma Stories Investors Were Pricing In

The shares cost US$40.78 at the start of the period, which left investors weighing two very different stories about where Royalty Pharma might head next.

On the optimistic side, the bull Narrative argued that the stock deserved a Fair Value of US$44.86, a rough guide to what its assumptions implied. That view leaned on revenue growing 20.0% a year and profit margins settling at 23.2%, helped by new licensing deals and ongoing share buybacks.

The bearish case pointed to a Fair Value of US$32.19 based on tougher conditions. That scenario focused on political and regulatory pressure on drug pricing as a key risk to future royalty streams and earnings stability.

What The Results Put To The Test For Royalty Pharma

Royalty Pharma’s Q3 2026 report gave the bullish narrative its cleanest test. Total revenue was US$690.1m versus US$609.3m a year earlier, which lined up with the growth-focused story. Net income excluding extra items was US$144.7m versus US$284.2m, and net margin compressed from 46.6% to 21.0%, which directly challenged the profitability assumptions. Overall, the evidence cut both ways.

The episode turned on one simple belief, that higher receipts would eventually land in steady earnings power. When you look at another stock built on a similar pitch, track whether rising sales are matched by stable or improving net margin rather than just headline revenue.

What Royalty Pharma’s Price Now Asks You To Believe

Royalty Pharma trades at US$67.3 today, with the bullish analyst Narrative on Simply Wall St suggesting a Fair Value that sits above that market level rather than below it. That view leans on a model where portfolio receipts and earnings reflect disciplined capital deployment rather than one off luck.

The Narrative’s argument hinges on high margin royalty funding, expanding deal channels and data heavy underwriting. A prospective buyer now has to decide whether Royalty Pharma can keep sourcing attractive royalty and R&D co funding agreements at terms that protect its historic return profile.

"Royalty Pharma has built an R&D co-funding franchise with large pharmaceutical companies, including recent US$500m commitments with Teva and Johnson & Johnson that are booked as contra R&D for partners. Management now describes this as a potential multibillion dollar per year funding channel that expands its access to top priority late stage assets and creates a recurring source of higher return development stage royalties, which can support portfolio receipts and earnings."

The price and this Narrative do not agree. → Uncover what this Narrative says Royalty Pharma is actually worth

Find Your Own Contrarian Opportunity

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 49% below our estimate - runs an asset-light hotel network while adding a technology-enabled retail marketplace.
• Company 2 - 40% below our estimate - handles air and ocean freight and manages customs for complex cargo movements.
• Company 3 - 39% below our estimate - advises on failure analysis, safety investigations, and technically complex regulatory disputes.

That is three of the list. See the full list of 25 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com